IGMS - igmbio.com Debt to Book Capitalization Ratio

Graphic logo of IGM Biosciences (IGMS)

The ratio of attracted funds to book capitalization visualizes long-term capital dynamics, where the value 0.00 shows the current magnitude. The growth of IGM Biosciences, Inc. (IGMS) relies on successes in IgM antibody development and collaboration with Sanofi. Platform safety and tumor targeting precision determine the success of the tests. The company is currently executing a strategic pivot, focusing all resources on the treatment of autoimmune pathologies.

IGMS (IGM Biosciences) Debt to Book Value history from 07/04/2022 to 08/24/2025
Core merchandise of igmbio.com

Investors assess fundamental capital risks by analyzing the business's debt sustainability. For IGM Biosciences, Inc. (IGMS), it is critically important to retain a staff of rare clinical phase experts through stock option programs. The ratio of financial debt to book capitalization reflects the proportion of borrowed funds relative to equity. Low values minimize default risk but may limit expansion. The balance of this indicator determines the company's ability to fund scientific research and development without sacrificing financial independence.

Who IGM Biosciences, Inc. competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Debts to Book Capitalization IMNM (Immunome Corp)|GOSS - Debts to Net Assets|Debts to Book Capitalization KALV (KalVista Pharmaceuticals)|SEPN (septerna.com) - Debt to Net Assets|Debt to Book Capitalization Ratio PVLA|Debt to Book Value Savara Inc (SVRA)|Rigel Pharmaceuticals Inc (RIGL) - Debt to Book Value|Debt to Net Assets Ratio AnaptysBio Inc. (ANAB)|Debts to Book Capitalization Astria Therapeutics ATXS|Debt to Book Capitalization Ratio engene.com ENGN|Debts to Book Capitalization RAPT (RAPT Therapeutics, Inc.)|JBIO: Debts to Net Assets|Debt to Book Capitalization Ratio ACRS|KYTX (Kyverna Therapeutics, Inc) - Debts to Book Value|TLSA: Debt to Book Capitalization Ratio|Debts to Net Assets cabalettabio.com|Debts to Book Capitalization VTYX (Ventyx Biosciences, Inc.)|Debt to Book Value Theratechnologies, Inc. (THTX)|Debts to Book Capitalization AVTX|Debts to Net Assets Eledon Pharmaceuticals, Inc ELDN|AGEN (Agenus) - Debts to Book Capitalization|CLYM: Debts to Book Value|Debt to Book Capitalization Ratio Zura Bio Limited|aTyr Pharma Inc (ATYR) - Debt to Book Value Ratio|Debts to Book Capitalization ADAG|Debt to Book Value Ikena Oncology, Inc.|Shattuck Labs, Inc. - Debts to Book Capitalization|Debts to Book Value EQ (equilliumbio.com)|Debt to Book Capitalization Ratio CNTB|IMUX - Debts to Net Assets|Debt to Book Value Atara Biotherapeutics Inc (ATRA)|IFRX - Debt to Net Assets Ratio|X4 Pharmaceuticals - Debts to Book Capitalization|ACET (Adicet Bio, Inc.) - Debts to Net Assets|Debt to Book Capitalization Ratio Celularity Inc (CELU)|Debt to Book Value Ratio INmune Bio Inc|Debts to Book Capitalization BRNS (Barinthus Bio)|Debt to Book Value Kezar Life Sciences Inc KZR|Debt to Book Value SABS|Debts to Net Assets akaritx.com AKTX|Debts to Book Capitalization ENLV (Enlivex Therapeutics, Ltd.)|QTTB - Debts to Net Assets|Debts to Book Capitalization GOVX (GeoVax Labs Inc)|EDSA (Edesa Biotech Corp) - Debt to Net Assets|Debt to Book Capitalization Ratio IBIO|Debt to Book Value CARM|XTLB (XTL Biopharmaceuticals Ltd.) - Debt to Book Capitalization Ratio|Debts to Net Assets BOLT (boltbio.com)|HCW Biologics (HCWB) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Aptevo Therapeutics, Inc. APVO|Debts to Book Capitalization AIM ImmunoTech (AIM)|ADTX - Debt to Net Assets Ratio|GRI: Debts to Book Capitalization|XRTX (XORTX Therapeutics Inc) - Debts to Book Capitalization|HIND - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio REVB|Debt to Book Capitalization Ratio INDP (Indaptus Therapeutics)|Debt to Book Value scinai.com (SCNI)|Debts to Book Capitalization CALI (CalciMedica)|AFMD - Debts to Book Capitalization|Debt to Book Value Allakos Therapeutics (ALLK)|HOOK - Debt to Net Assets Ratio|iTeos Therapeutics - Debts to Book Capitalization|OCEA (oceanbiomedical.com) - Debts to Net Assets|Debt to Book Capitalization Ratio TCBP|Debt to Book Value THRD